Seeking Alpha

Privately held Ocera Therapeutics (a developer of liver disease treatments) will merge with a...

Privately held Ocera Therapeutics (a developer of liver disease treatments) will merge with a subsidiary of Tranzyme Pharmaceuticals (TZYM) in an all-stock deal. The companies say the merged entity (which will assume the "Ocera" name and will be 72.6% owned by Ocera shareholders) will be a NASDAQ-listed company. Tranzyme will issue $20M in common stock and effect a reverse stock split concurrently with the closing of the deal. (See: TZYM to evaluate alternatives)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|